arrow
D

Diego Malón

Hospital La Paz Institute for Health Research and Universidad Autónoma de Madrid and Getafe University Hospital and Universidad Europea de Madrid
H指数:10
被引数:369

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors

与接受免疫检查点抑制剂治疗的黑色素瘤患者免疫相关肝炎相关的肿瘤SNPs

2026-03-030
OAAI
Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer

曲妥珠单抗作为新辅助治疗用于HER2阳性早期乳腺癌的安全性和有效性:多柔比星和环磷酰胺序贯剂量密集(每2周)紫杉醇的方案

2025-04-280
PRE
Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab plus /- pertuzumab (TCH/TCHP): a correlative analysis from a multicenter academic study
2023-03-010
PRE
Features and survival outcomes of HER2-low patients from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
2023-03-010
PRE
Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)
2023-03-010
PRE
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

在经过大量预处理的HR /HER2晚期乳腺癌患者中,Palbociclib与内分泌治疗相结合: 西班牙同情使用计划 (PALBOCOMP) 的结果

BREAST
IF7.9
2020-12-018
OAAI
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

免疫引发durvalumab联合贝伐单抗治疗HER2-negative晚期乳腺癌的临床试验

2020-11-1122
OAAI
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

尼达尼布联合来曲唑治疗早期乳腺癌: FGFR1和芳香化酶联合抑制的0/I期药效学、药代动力学和安全性临床试验

2019-05-2418
OAAI
Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)
2017-02-150
PRE